1. Petruzziello, A, Marigliano, S, Loquercio, G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22: 7824–7840.
Google Scholar | Crossref | Medline2. European Association for the Study of the Liver . EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199–236.
Google Scholar | Crossref | Medline3. European Association for the Study of the Liver . EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol 2020; 73: 1170–1218.
Google Scholar | Crossref | Medline4. World Health Organization (WHO) . Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/ (2018, accessed 1 June 2021).
Google Scholar5. World Health Organization (WHO) . Global hepatitis report, https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (2017, accessed 1 June 2021).
Google Scholar6. Sanyal, AJ, Yoon, SK, Lencioni, R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15(Suppl. 4): 14–22.
Google Scholar | Crossref | Medline7. European Association for the Study of the Liver . EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659–689.
Google Scholar | Crossref | Medline8. Poynard, T, Moussalli, J, Munteanu, M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675–683.
Google Scholar | Crossref | Medline9. Shiffman, ML, Sterling, RK, Contos, M, et al. Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol 2014; 13: 340–349.
Google Scholar | Crossref | Medline10. George, SL, Bacon, BR, Brunt, EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729–738.
Google Scholar | Crossref | Medline11. Cammà, C, Di Bona, D, Schepis, F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333–342.
Google Scholar | Crossref | Medline12. Abergel, A, Darcha, C, Chevallier, M, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 2004; 16: 1219–1227.
Google Scholar | Crossref | Medline13. Toccaceli, F, Laghi, V, Capurso, L, et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126–133.
Google Scholar | Crossref | Medline14. Poynard, T, McHutchison, J, Manns, M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.
Google Scholar | Crossref | Medline15. Kojima, H, Hongo, Y, Harada, H, et al. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001; 16: 1015–1021.
Google Scholar | Crossref | Medline16. Shiratori, Y, Imazeki, F, Moriyama, M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517–524.
Google Scholar | Crossref | Medline17. Kurosaki, M, Matsunaga, K, Hirayama, I, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48: 736–742.
Google Scholar | Crossref | Medline18. Goodman, ZD . Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598–607.
Google Scholar | Crossref | Medline19. Bedossa, P, Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289–293.
Google Scholar | Crossref | Medline20. Kleiner, DE, Brunt, EM, Van Natta, M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
Google Scholar | Crossref | Medline21. Sanchez, EL, Lagunoff, M. Viral activation of cellular metabolism. Virology 2015; 479–480: 609–618.
Google Scholar | Crossref | Medline22. Schneider, WJ, Beisiegel, U, Goldstein, JL, et al. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem 1982; 257: 2664–2673.
Google Scholar | Crossref | Medline23. Syed, GH, Tang, H, Khan, M, et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2014; 88: 2519–2529.
Google Scholar | Crossref | Medline24. Siagris, D, Christofidou, M, Theocharis, GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56–61.
Google Scholar | Crossref | Medline25. Hammerstad, SS, Grock, SF, Lee, HJ, et al. Diabetes and hepatitis C: a two-way association. Front Endocrinol (Lausanne) 2015; 6: 134.
Google Scholar | Crossref | Medline26. Kasai, D, Adachi, T, Deng, L, et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 2009; 50: 883–894.
Google Scholar | Crossref | Medline27. Shoji, I, Deng, L, Hotta, H. Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. Front Microbiol 2012; 2: 278.
Google Scholar | Crossref | Medline28. Nakashima, K, Takeuchi, K, Chihara, K, et al. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. Microbiol Immunol 2011; 55: 774–782.
Google Scholar | Crossref | Medline29. Mankouri, J, Tedbury, PR, Gretton, S, et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A 2010; 107: 11549–11554.
Google Scholar | Crossref | Medline30. Tai, W-C, Hu, T-H, Wang, J-H, et al. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc 2009; 108: 210–218.
Google Scholar | Crossref | Medline31. Bruce, MG, Bruden, D, McMahon, BJ, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. J Viral Hepat 2008; 15: 179–187.
Google Scholar | Crossref | Medline32. Hu, K-Q, Kyulo, NL, Lim, N, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 860–865.
Google Scholar | Crossref | Medline33. Kuhlmann, WD, Peschke, P. Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol 2006; 87: 343–359.
Google Scholar | Crossref | Medline34. Yu, ML, Chuang, WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336–345.
Google Scholar | Crossref | Medline35. Rockey, DC, Friedman, SL. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. Gastroenterology 2021; 160: 1502–1520.
Google Scholar | Crossref | Medline